

U.S. Securities and Exchange Commission
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 30, 2005

ORTHODONTIX, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida (State or other jurisdiction of incorporation)	000-27836 Commission File Number	65-0643773 (IRS Employer Identification No.)
--------------------------------------------------------------	----------------------------------------	----------------------------------------------------

1428 Brickell Avenue, Suite 105
Miami, Florida 33131
(Address of principal executive offices)

(305) 371-4112
(Registrant's Telephone Number)

Not Applicable
(Former name, former address and former fiscal year,
if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

On November 30, 2005, Orthodontix, Inc. (the "Company") sold 2,915,428 newly issued shares of common stock, par value \$.0001, to Frost Gamma Investments Trust, of which Dr. Phillip Frost is the trustee and beneficiary. The purchase price was \$494,000.00. There were no underwriting discounts or commissions. The Company relied upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933 in making the sale to the trust.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit 99.1 Press Release dated December 6, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ORTHODONTIX, INC.
(Registrant)

Dated: December 6, 2005

By: /s/ Glenn L. Halpryn

Glenn L. Halpryn
Chief Executive Officer

Dr. Phillip Frost purchases control of Orthodontix, Inc.

MIAMI
December 6, 2005

On November 30, 2005, Dr. Phillip Frost, Chairman and CEO of Ivax Corporation, through a trust purchased control of Orthodontix, Inc. The trust paid \$494,000 for 2,915,428 newly issued shares. With the November purchase, the trust owns 2,965,428 shares or 51 percent of Orthodontix.

Orthodontix intends to effect a merger or other business combination with an operating company.

CONTACT: Orthodontix, Inc., Miami
Glenn L. Halpryn, 305-371-4112